UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 21, 2025

Actuate Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-42139

47-3044785

(State or Other Jurisdiction

of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

1751 River Run, Suite 400
Fort Worth, Texas

76107

(Address of Principal Executive Offices)

(Zip Code)

(817) 887-8455

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Common Stock, par value $0.000001 per share

ACTU

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Information.

Actuate Therapeutics Disclosure Channels to Disseminate Information

Actuate Therapeutics’ investors and others should note that we announce material information to the public about our company and its technologies, clinical and corporate developments, and other matters through a variety of means, including Actuate Therapeutics’ website, press releases, SEC filings, and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in the locations below as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Interested in keeping up with Actuate Therapeutics?

For more information on Actuate Therapeutics and its technology, clinical and corporate developments, and other matters, please visit: https://actuatetherapeutics.com.

For more information for Actuate Therapeutics’ investors, including press releases, SEC filings, corporate presentations, events, please visit: https://actuatetherapeutics.com/investors. Investors and other interested parties can subscribe to our press releases and SEC filings at the aforementioned address.

For additional information, please follow Actuate Therapeutics social media accounts at:

X account (formerly Twitter): @ActuateThera or https://x.com/ActuateThera

LinkedIn: https://www.linkedin.com/company/actuate-therapeutics-inc./

Facebook profile: https://www.facebook.com/profile.php?id=61572431561095

Investors and other interested parties can also subscribe to our social media accounts at the aforementioned addresses.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Actuate Therapeutics, Inc.

Date: November 21, 2025	By:	/s/ Daniel M. Schmitt
		Name: Daniel M. Schmitt
		Title: President and Chief Executive Officer

ACTUATE THERAPEUTICS, INC. 8-K